Seagen controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2019
Daiichi Sankyo files declaratory judgment action against Seattle Genetics
Lawsuit filed
Daiichi Sankyo filed a declaratory judgment action in the District Court of Delaware in a dispute with Seattle Genetics over rights to linker technology used in antibody-drug conjugates, including DS-8201. Seattle Genetics said Daiichi's filing circumvented the dispute-resolution process in their former agreement; both parties disputed the other's claims to the technology.
Source excerpt
“By filing this lawsuit, Daiichi Sankyo has circumvented the process underway between the parties pursuant to these provisions,” Seattle Genetics wrote in a statement responding to the legal action.
Daiichi revealed it has filed a declaratory judgement action in the District Court of Delaware.
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.